Key result
Circulating microRNAs emerge as promising diagnostic biomarkers for cardiovascular diseases and type 2 diabetes.
Answers are grounded in this paper and cite their sources.
One of the major challenges in cardiovascular disease is the identification of reliable clinical biomarkers that can be routinely measured in plasma. MicroRNAs (miRNAs) were recently discovered to circulate in the bloodstream in a remarkably stable form. Because of their stability and often tissue- and disease-specific expression and the possibility to measure them with high sensitivity and specificity, miRNAs are emerging as new diagnostic biomarkers. In this review we will provide an overview of the potential of circulating miRNAs as biomarkers for a wide range of cardiovascular diseases such as coronary artery disease, myocardial infarction, hypertension, heart failure, viral myocarditis, and type-2 diabetes mellitus. Furthermore, we will discuss the challenges with regard to further validation in large patient cohorts, and we will discuss how the measurement of multiple miRNAs simultaneously might improve the accuracy of the diagnostic test.
No takes yet. Share an insight, caveat, or question.
Tijsen et al. (2012) conducted a review in Cardiovascular diseases (coronary artery disease, myocardial infarction, hypertension, heart failure, viral myocarditis, and type-2 diabetes mellitus). Circulating microRNAs (miRNAs) was evaluated. Circulating microRNAs are emerging as diagnostic biomarkers for cardiovascular diseases, including heart failure and type-2 diabetes, though no quantitative results are reported in this review.
Synapse has enriched 10 related papers. Consider them for comparative context: